/INO

INO Stock - Inovio Pharmaceuticals, Inc.

Q: What is the analyst price target for INO?

Analyst price target information is not currently available for INO.

Q: What is INO's market cap?

Market capitalization information is not currently available for INO.

Healthcare|Biotechnology|NASDAQ

$2.28-3.80%

$0.09 (-3.80%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+163.2%upside

Target: $6.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for INO

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.55

52W High$2.98

52W Low$1.30

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$217,756	$832,010	$10.26M	$1.77M	$7.41M
Gross Profit	$217,756	$832,010	$10.26M	$1.77M	$7.41M
Gross Margin	100.0%	100.0%	100.0%	100.0%	100.0%
Operating Income	$-112,398,922	$-143,940,028	$-267,573,520	$-301,217,919	$-124,082,044
Net Income	$-107,254,126	$-135,117,352	$-279,818,065	$-303,658,710	$-166,411,157
Net Margin	-49254.3%	-16239.9%	-2726.7%	-17109.9%	-2245.4%
EPS	$-3.95	$-6.09	$-14.07	$-1.42	$-1.07

Company Overview

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

33%

Hold / Neutral

33%

Sell / Underperform

33%

Analyst Consensus🔴 Bearish

1 Bullish2 Neutral/Bearish

Price Targets

Average Target

↑ 207.0% Upside

Now

Low

Average

$20

High

Based on 5 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
July 9th 2025	Piper Sandler	Initiation	Overweight	$5
May 14th 2024	Stephens	Initiation	Overweight	$20
January 25th 2024	Oppenheimer	Upgrade	Outperform	$4
November 9th 2022	Maxim Group	Downgrade	Hold	-
November 1st 2022	BofA Securities	Downgrade	Underperform	$2
July 19th 2022	RBC Capital Mkts	Resumed	Sector Perform	$4← $5
May 11th 2022	Oppenheimer	Downgrade	Perform	-

Earnings History & Surprises

INO

Beat Rate

56%

Last 18 quarters

Avg Surprise

-3.1%

EPS vs Estimate

Beats / Misses

10/8

Last 12 quarters

Latest EPS

$-0.44

Q4 2025

EPS Surprise History

Q1 24

+11.8%

$-1.12vs$-1.27

Q2 24

-21.3%

$-1.31vs$-1.08

Q3 24

-3.5%

$-1.19vs$-1.15

Q4 24

+25.8%

$-0.89vs$-1.20

Q1 25

+20.7%

$-0.69vs$-0.87

Q2 25

+31.1%

$-0.51vs$-0.74

Q3 25

+3.2%

$-0.61vs$-0.63

Q4 25

+13.7%

$-0.44vs$-0.51

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 11, 2026	—	—	—	—
Q1 2026	Mar 17, 2026	$-0.37	—	—	—
Q4 2025	Nov 10, 2025	$-0.51	$-0.44	+13.7%	✓ BEAT
Q3 2025	Aug 12, 2025	$-0.63	$-0.61	+3.2%	✓ BEAT
Q2 2025	May 13, 2025	$-0.74	$-0.51	+31.1%	✓ BEAT
Q1 2025	Mar 18, 2025	$-0.87	$-0.69	+20.7%	✓ BEAT
Q4 2024	Nov 14, 2024	$-1.20	$-0.89	+25.8%	✓ BEAT
Q3 2024	Aug 8, 2024	$-1.15	$-1.19	-3.5%	✗ MISS
Q2 2024	May 13, 2024	$-1.08	$-1.31	-21.3%	✗ MISS
Q1 2024	Mar 6, 2024	$-1.27	$-1.12	+11.8%	✓ BEAT
Q4 2023	Nov 9, 2023	$-1.56	$-1.08	+30.8%	✓ BEAT
Q3 2023	Aug 9, 2023	$-1.68	$-1.56	+7.1%	✓ BEAT
Q2 2023	May 10, 2023	$-1.68	$-1.92	-14.3%	✗ MISS
Q1 2023	Mar 1, 2023	$-1.92	$-2.52	-31.3%	✗ MISS
Q4 2022	Nov 8, 2022	$-3.48	$-1.80	+48.3%	✓ BEAT
Q3 2022	Aug 9, 2022	$-3.60	$-5.52	-53.3%	✗ MISS
Q2 2022	May 10, 2022	$-3.36	$-4.32	-28.6%	✗ MISS
Q1 2022	Mar 1, 2022	$-3.96	$-6.00	-51.5%	✗ MISS
Q4 2021	Nov 9, 2021	$-3.96	$-3.48	+12.1%	✓ BEAT
Q3 2021	Aug 9, 2021	$-3.00	$-4.68	-56.0%	✗ MISS

Frequently Asked Questions about INO

What is INO's current stock price?

Inovio Pharmaceuticals, Inc. (INO) is currently trading at $2.28 per share. The stock has moved -3.80% today.

What is the analyst price target for INO?

The average analyst price target for INO is $6.00, based on 1 analyst.

What sector is Inovio Pharmaceuticals, Inc. in?

Inovio Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is INO's market cap?

Inovio Pharmaceuticals, Inc. has a market capitalization of $0.12 billion, making it a small-cap company.

Does INO pay dividends?

No, Inovio Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.